{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:46:57Z","timestamp":1792669617030,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.eururo.2014.09.019","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T17:42:58Z","timestamp":1412703778000},"page":"1160-1167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"title":["Nomogram Predicting Prostate Cancer\u2013specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy"],"prefix":"10.1016","volume":"67","author":[{"given":"John A.","family":"Brockman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Alanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Scardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Bianco Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay P.","family":"Ciezki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.09.019_bib0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jnci\/djj190","article-title":"Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy","volume":"98","author":"Stephenson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.09.019_bib0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0094-0143(05)70163-4","article-title":"Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience","volume":"28","author":"Han","year":"2001","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2014.09.019_bib0015","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.09.019_bib0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer\u2013specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.09.019_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2005.06.116","article-title":"Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (\u201ctrifecta\u201d)","volume":"66","author":"Bianco","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2014.09.019_bib0185","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/JCO.2002.03.061","article-title":"Determinants of prostate cancer\u2013specific survival after radiation therapy for patients with clinically localized prostate cancer","volume":"20","author":"D\u2019Amico","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0035","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1200\/JCO.2005.01.2906","article-title":"Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy","volume":"23","author":"Zhou","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0040","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1200\/JCO.2005.06.058","article-title":"Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy","volume":"23","author":"Dotan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0045","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1158\/1078-0432.CCR-05-1668","article-title":"Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy","volume":"11","author":"Slovin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.09.019_bib0050","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/jnci\/djg043","article-title":"Surrogate end point for prostate cancer\u2013specific mortality after radical prostatectomy or radiation therapy","volume":"95","author":"D\u2019Amico","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.09.019_bib0055","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.juro.2008.01.099","article-title":"Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time","volume":"179","author":"Arlen","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0060","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0065","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.09.019_bib0070","series-title":"An introduction to the bootstrap","author":"Efron","year":"1993"},{"key":"10.1016\/j.eururo.2014.09.019_bib0075","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2014.09.019_bib0080","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/jco.2004.22.14_suppl.4642","article-title":"Predicting time to metastatic progression from biochemical recurrence after radical prostatectomy","volume":"22","author":"Dotan","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0085","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","article-title":"Predicting 15-year prostate cancer specific mortality after radical prostatectomy","volume":"185","author":"Eggener","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jnci\/djr028","article-title":"An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection","volume":"103","author":"Vickers","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.09.019_bib0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2008.18.1685","article-title":"Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer","volume":"27","author":"Vickers","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0100","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1200\/JCO.2008.18.2501","article-title":"Prostate cancer\u2013specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era","volume":"27","author":"Stephenson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2004.07.099","article-title":"Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group","volume":"22","author":"Scher","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0110","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.2010.32.2776","article-title":"Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study","volume":"29","author":"Dorff","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0115","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.09.019_bib0120","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial","volume":"191","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0125","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer\u2013specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.09.019_bib0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2013.08.036","article-title":"Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality","volume":"65","author":"Stephenson","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.019_bib0140","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2008.09.008","volume":"55","author":"Schr\u00f6der","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-5347(05)65972-1","article-title":"A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment","volume":"166","author":"Walsh","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.09.019_bib0155","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.019_bib0160","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.019_bib0165","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.019_bib0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.019_bib0175","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.09.019_bib0180","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814009567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814009567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T14:17:20Z","timestamp":1529677040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814009567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0302283814009567"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.09.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nomogram Predicting Prostate Cancer\u2013specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}